Thus, there is an increased expression of the immune inhibitory molecules PD-L1 and CTLA-4 in COSCC tumor cells that also display active EMT signaling, suggesting that COSCC patients could potentially benefit from immune checkpoint inhibitor therapies. The gene discussed is CTLA4; the disease is neoplasm.